HMGCR and coronary artery disorder: This finding was consistent with the observed reduction in CAD risk with statins, drugs that inhibit the protein product of HMGCR. Discovery of the parallel mechanisms behind the disease-associated SNP’s effect on low density lipoprotein cholesterol levels and subsequent disease and the effects of cholesterol-lowering statins on the same target helped focus research efforts on SNPs affecting other blood lipids to determine if additional genetic associations with reduced CAD risk may lead to the development of novel therapeutic agents[3].